^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
fidasimtamab (IBI315)
i
Other names: IBI315, BH2950
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Hanmi, Innovent Biologics
Drug class:
PD1 inhibitor, HER2 inhibitor
Related drugs:
6ms
Anti-PD-1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2-Positive Gastric Cancer through Gasdermin B-Cleavage Induced Pyroptosis. (PubMed, Adv Sci (Weinh))
Notably, GSDMB is found to be elevated in Her2-positive gastric cancer cells, providing a rationale for IBI315's efficacy. IBI315 is supported here as a promising bispecific antibody-based immunotherapy approach for Her2-positive gastric cancer in preclinical studies, broadening the therapeutic landscape of this patient population.
Journal • PD(L)-1 Biomarker • IO biomarker
|
IFNG (Interferon, gamma) • GSDMB (Gasdermin B)
|
HER-2 positive • EGFR positive • IFNG expression • GSDMB expression • HER-2 elevation • PD-1 positive
|
fidasimtamab (IBI315)
6ms
A Phase Ia/Ib Study of IBI315 in Patients With HER2-expressing Advanced Solid Tumor (clinicaltrials.gov)
P1a/1b, N=55, Completed, Innovent Biologics (Suzhou) Co. Ltd. | Recruiting --> Completed | N=191 --> 55 | Trial completion date: Dec 2025 --> Jun 2023
Trial completion • Enrollment change • Trial completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression
|
fidasimtamab (IBI315)
over1year
Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes (clinicaltrials.gov)
P1/2; N=45; Not yet recruiting; Sponsor:Henan Cancer Hospital
New P1/2 trial • IO biomarker
|
PD-L1 IHC 22C3 pharmDx
|
Focus V (anlotinib) • capecitabine • oxaliplatin • benmelstobart (APL-502) • osemitamab (TST001) • fidasimtamab (IBI315)
Share via
